03-Mar-2008 - A long-acting injectable formulation of Eli Lilly's blockbuster schizophrenia treatment Zyprexa (olanzapine), with the potential to improve patient adherence and take some of the sting out of generic competition three years down the line, has fallen at the final hurdle before US approval.

Link to Article

In-Pharmatechnologist.com